Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

News SummaryMost relevantAll newsSector newsTweets

FDA Approves Kadcyla, Breast-Cancer Drug from Roche, ImmunoGen

share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2013 | 05:26pm CEST
   By Jennifer Corbett Dooren 

WASHINGTON--The U.S. Food and Drug Administration Friday approved a powerful new type of drug that will be marketed by Roche Holding AG (ROG.VX, RHHBY) to treat breast cancer.

The drug called, Kadcyla, combines Roche's existing cancer drug, Herceptin, with a powerful chemotherapy agent.

Herceptin targets a protein called HER2 found on tumors in about 20% to 25% of breast-cancer patients. The two other components of Kadcyla, both developed by ImmunoGen Inc. (>> ImmunoGen, Inc.), are a chemotherapy agent called emtansine that is too potent to be delivered as a conventional medicine, and a linker that connects the two drugs. Herceptin then delivers the package to the tumor cell, where it releases the toxic cargo to kill the cancer.

The FDA's approval of Kadcyla, which was previously known as T-DM1, triggers a $10.5 million payment to ImmunoGen by Roche. ImmunoGen will also receive royalties on sales.

Roche's Genentech unit said Kadcyla will be available to patients in about two weeks. The drug will be priced at $9,800 a month. The company said there will be a patient-assistance program to help pay for the product.

The approval of Kadcyla was based on a study of about 1,000 women with HER2-positive breast cancer who had been treated previously with Herceptin and a traditional chemotherapy drug. About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline PLC's (GSK, GSK.LN) Tykerb. The drugs were administered every three weeks until the disease progressed or patients experienced unmanageable side effects.

The study was designed to measure progression-free survival, which is a measurement of the time from the start of treatment until the disease gets worse or the patient dies, and overall survival, which is a measurement of time from the start of treatment until death.

The median progression-free survival for patients receiving T-DM1 was 9.6 months, compared with 6.4 months in the group receiving Xeloda and Tykerb, a difference considered statistically significant. The median overall survival was 30.9 months in the Kadcyla group and 25.1 months for Xeloda and Tykerb group.

Write to Jennifer Corbett Dooren at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : ImmunoGen, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on IMMUNOGEN, INC.
10/20 IMMUNOGEN : Announces Conference Call to Discuss Its Third Quarter 2017 Financia..
10/17 IMMUNOGEN : Announces Investigational New Drug Application for IMGN632 for Hemat..
10/17 FDA FINALIZES REVIEW OF IMMUNOGEN, I : IMGN) Investigational New Drug Applicatio..
10/16 IMMUNOGEN : Announces Investigational New Drug Application for IMGN632 for Hemat..
10/12 IMMUNOGEN,INC. (NASDAQ : IMGN) Files An 8-K Other Events
10/11 IMMUNOGEN : Announces Closing of Public Offering of Common Stock, Including Full..
10/11 IMMUNOGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
10/11 IMMUNOGEN : Announces Closing of Public Offering of Common Stock, Including Full..
10/06 IMMUNOGEN INC : Entry into a Material Definitive Agreement, Other Events, Financ..
10/06 IMMUNOGEN : Announces Pricing of Public Offering of Common Stock
More news
News from SeekingAlpha
10/06 PREMARKET LOSERS AS OF 9 : 05 am
10/06 ImmunoGen prices 14.5M shares of common stock offering at $6.50; shares off 2..
10/05 PREMARKET LOSERS AS OF 9 : 05 am
10/04 After Hours Gainers / Losers
10/04 ImmunoGen readies 13M-share stock offering; shares down 3% after hours
Financials ($)
Sales 2016 69,2 M
EBIT 2016 -113 M
Net income 2016 -131 M
Debt 2016 19,2 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 9,78x
EV / Sales 2017 6,23x
Capitalization 658 M
Duration : Period :
ImmunoGen, Inc. Technical Analysis Chart | IMGN | US45253H1014 | 4-Traders
Technical analysis trends IMMUNOGEN, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 9,17 $
Spread / Average Target 56%
EPS Revisions
Mark J. Enyedy President, Chief Executive Officer & Director
Stephen C. McCluski Chairman
David B. Johnston Chief Financial Officer & Executive Vice President
Richard J. Gregory Chief Scientific Officer & Executive VP
Anna Berkenblit Chief Medical Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOGEN, INC.202.45%658
LONZA GROUP59.15%19 392
CELLTRION, INC.--.--%19 297